Guides H2 $6.25-6.65 (no comparable ests), Rev above $8B (no comparable ests); cites adjustments due to divestiture to Teva
- H2 EBIT seen at $3.8-4.0B
- The transaction with Teva is expected to close in the first quarter of 2016.
Following the close of the divestiture of the Generics business to Teva, New Allergan expects to have a powerful financial profile to drive continued long-term growth:
10% branded revenue growth
Non-GAAP gross margins of 77% to 79% with additional long-term expansion anticipated
Non-GAAP SG&A as a percentage of revenue between 21-24%, declining within that range over time
Non-GAAP tax rate of ~15%